Clausen, Valerie A.
Alnylam Pharmaceuticals (United States) · St George's, University of London · The University of Texas Southwestern Medical Center
2 papers on CoChatORCID 0009-0006-2901-9540
Most cited papers
- Verified
Safety and efficacy of RNAi therapy for transthyretin amyloidosis
Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P. N., Mant, T., Perez, J., Chiesa, J., Warrington, S., Tranter, E., et al. (2013) · New England Journal of Medicine
Amyloidosis: Diagnosis, Treatment, OutcomesRNA Interference and Gene Delivery
Cited by 971
- Verified
A highly durable RNAi therapeutic inhibitor of PCSK9
Fitzgerald, K., White, S., Borodovsky, A., Bettencourt, B. R., Strahs, A., Clausen, V., Wijngaard, P., Horton, J. D., Taubel, J., Brooks, A., et al. (2017) · New England Journal of Medicine
Lipoproteins and Cardiovascular HealthRNA Interference and Gene Delivery
Cited by 768
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free